louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00996450: Educational Follow-up in a Cohort of Children at the Royal Marsden Hospital (RMH)
Official title: Educational Follow-up in a Cohort of Children at the Royal Marsden Hospital, Following the Treatment of a Brain Tumour
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Tumour
Keywords: brain tumour
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
First posted: 2009-10-16
Enrollment: 110
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cases will be identified by looking at RMH coding database. Medical information will be sort from the electronic patient records (EPR) and from the patient notes.

Brief summary: To document pre-diagnosis educational abilities, to document any change in educational achievements following treatment, to document educational support given within the statement process and to document the timing of support.

Detailed description: This will be a retrospective study. Cases will be identified by looking at the Royal Marsden Hospital (RMH) coding database. All the patients will have completed treatment for a brain tumour. The children all need to have started school before the diagnosis of their brain tumour so that we can look at easily defined educational assessments in this cohort. Children will be identified by looking at RMH coding of diagnosis and include children aged between 4 years and 18 years old (school age).

Eligibility criteria: Inclusion Criteria:

* patients/parental consent for RMH accessing educational information from them and their school
* patients with a primary brain tumour

Exclusion Criteria:

* children with secondary brain tumours
* children who have had treatment for a relapse of primary brain tumour

Primary outcomes:
Secondary outcomes:
measure: To compare educational achievements of children of different tumour types following treatment.
measure: To document if there are any differences in educational achievements depending on the age at diagnosis of the brain tumour.
Other outcomes:
Locations:
city: Belmont
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
state: Surrey
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: Dr Darren Hargrave
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06906250: European Venous Registry
Official title: European Venous Registry
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Deep Venous Disease of the Lower Limbs
Keywords: acute or chronic lower limb deep venous disease
iliac and/or common femoral veins
inferior vena cava
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2025-04-02
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population sampled for data collection includes all patients suffering from deep venous disease of the lower limbs who are treated in the centres joining the registry. These include patients receiving surgery as well as those not receiving surgery. Only prospective patients will be allowed.

Brief summary: The European Venous Registry (EVeR) is an international repository of data on the treatments and outcomes of people with deep venous disease. The registry is designed to evaluate the outcomes of venous interventions over a ten-year period, with the ultimate goal to inform clinical decision making through the delivery of scientific evidence.


Eligibility criteria: Inclusion Criteria:

* Patients with an imaging-confirmed new diagnosis of acute or chronic lower limb deep venous disease involving the iliac and/or common femoral veins, with or without extension to the inferior vena cava, or patients with an imaging-confirmed new diagnosis involving the IVC only.
* Consent to enter registry.

Exclusion Criteria:

* Unable to consent to enter into registry.
* Isolated upper limb DVT.
* Central venous thrombosis (e.g. superior vena cava obstruction).
* Isolated deep vein thrombosis below the common femoral vein.
* Isolated superficial venous thrombosis.
* Isolated superficial venous thrombophlebitis.
* Isolated varicose veins.
* Aged \<18 years.

Primary outcomes:
measure: Clinical Severity Scores
timeFrame: end of the procedure
Secondary outcomes:
measure: Venous Insufficiency Epidemiological and Economic Study/Quality of Life (VEINES-QOL)
timeFrame: 10 years
Other outcomes:
Locations:
city: Marseille
country: France
facility: Department of Vascular Surgery
city: Aachen-Maastricht
country: Germany
facility: European Venous Center
city: Athens
country: Greece
facility: Clinic of Vascular and Endovascular Surgery at Athens Medical Group
city: Galway
country: Ireland
facility: Interventional Radiology, Galway University Hospitals
city: Milan
country: Italy
facility: IRCCS San Raffaele Hospital
city: Rotterdam
country: Netherlands
facility: Department of Vascular and Endovascular Surgery, Erasmus Medical Centre
city: Madrid
country: Spain
facility: Vascular and Endovascular Department, Viamed Hospitals
city: Istanbul
country: Turkey
facility: Department of Cardiovascular Surgery, Acibadem University School of Medicine,
city: Bristol
country: United Kingdom
facility: North Bristol NHS Trust
city: London
country: United Kingdom
facility: St Thomas' Hospital
Study officials:
References:
Clinical trial NCT04115150: Short-term Outcome After Ventral Hernia Repair
Official title: Short-term Outcome After Ventral Hernia Repair Using Self-gripping Mesh in Subway Technique - a Retrospective Cohort Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Short-term Outcome After Ventral Hernia Repair
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2019-10-03
Enrollment: 244
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A retrospective single-centre cohort study was performed for the time period of January 2011 to July 2018. All patients, receiving a ventral hernia repair (including incisional, umbilical or epigastric hernias) in Rives-Stoppa retromuscular mesh placement technique (sublay), were included into the final analysis.

Brief summary: Hernia repair in sublay technique is widely accepted for ventral hernias, as it appears to be advantageous in terms of complication and recurrence rates. Recently, self-gripping meshes are increasingly used for hernia repair with retromuscular mesh positioning. However, real-life data on the safe use in that specific indication are still lacking. Therefore, this study evaluated short-term postoperative outcome of self-gripping versus conventional non-self-gripping meshes in sublay hernia repair.


Eligibility criteria: Inclusion Criteria:

* ventral hernia repair in sublay technique

Exclusion Criteria:

* ventral hernia repair in other technique

Primary outcomes:
measure: Complication rate
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01622855: Acute Intervention to Reduce Distress Following Sexual Assault
Official title: Prevention of Post-Rape Psychopathology and Drug Abuse
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Drug Use
Drug Abuse
Posttraumatic Stress Disorder
Keywords: Rape
Secondary prevention
Intervention
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2012-06-19
Enrollment: 442
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study was to evaluate whether a brief intervention in video format delivered in the post assault medical exam setting and including education about assault reactions and instruction in and modeling of successful coping strategies would reduce post assault drug use or abuse and PTSD symptoms as compared to standard care.

Detailed description: The intervention being evaluated was shown at the time of the post assault medical exam and includes two main components: preparation for the medical exam; and information about and modelling of coping strategies that may help women cope in the aftermath of assault. The intervention content is delivered via video. Intervention and standard care groups were compared with regard to measures of substance use and abuse and symptoms of PTSD and other potentially comorbid problems including symptoms of depression or other anxiety.

Eligibility criteria: Inclusion Criteria:

* Seeking medical care after recent sexual assault

Exclusion Criteria:

* Active psychosis
* Active suicidality
* Cognitive impairment
* Non-English speaking
* Severe injury

Primary outcomes:
measure: Frequency of specific drug use
timeFrame: 14 days
Secondary outcomes:
measure: Specific Drug Abuse
timeFrame: 1.5, 3, 6 months
measure: PSS-SR
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
affiliation: Medical University of South Carolina
name: Heidi Resnick, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05918523: A Long-Term Follow-Up Study of Participants Exposed to REACT
Official title: A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Diabetic Kidney Disease
Chronic Kidney Diseases
Keywords: REACT
DKD
CKD
Lead sponsor: Prokidney
Sponsor class: INDUSTRY
First posted: 2023-06-26
Enrollment: 80
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with CKD

Brief summary: The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).

Detailed description: This observational extension study is a multi-center, prospective, non-therapeutic study, where up to 80 participants who have been enrolled and dosed with Renal Autologous Cell Therapy in previous interventional clinical studies (RMCL-002, REGEN-003, REGEN-004) will be monitored for up to five years with alternating in clinic and phone visits.

Eligibility criteria: Inclusion Criteria:

* The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.

Exclusion Criteria:

* The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.

Primary outcomes:
measure: Primary Endpoint: Long-term safety of REACT
timeFrame: 60 months from completion of parent protocol EOS Visit
Secondary outcomes:
measure: First Secondary Endpoint: Time from first injection to eGFR <15 mL/min/1.73m²
timeFrame: 60 months from completion of parent protocol EOS Visit
measure: Second Secondary Endpoint: Time from first injection to chronic dialysis.
timeFrame: 60 months from completion of parent protocol EOS Visit
measure: Third Secondary Endpoint: Time from first injection to renal transplant.
timeFrame: 60 months from completion of parent protocol EOS Visit
Other outcomes:
Locations:
city: Meridian
country: United States
facility: Boise Kidney & Hypertension Institute
state: Idaho
Study officials:
affiliation: Prokidney
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00000323: Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
Official title: Therapeutic Potential of Kappa-Opioids Against Cocaine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cocaine-Related Disorders
Keywords: cocaine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 1999-09-21
Enrollment: 10
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes

Brief summary: The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.


Eligibility criteria: Inclusion Criteria:

opiate experienced, healthy

Exclusion Criteria:

physical dependence on opioids, barbiturates or alcohol

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University (BPRU) Bayview Campus
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Sharon Walsh, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001 Sep;157(2):151-62. doi: 10.1007/s002130100788.
Clinical trial NCT01640223: Creation of a Patient Database for Silicon Patient Simulation, Glucose Sensor Variability and Pharmacokinetic Study of Debiotech Jewelpump
Official title: SEMI-CLOSED LOOP "FOR THE CONTROL OF BLOOD GLUCOSE IN DIABETIC SUBJECTS DIABELOOP First CLINICAL PROJECT: Under Project 3 (UP3), CREATING A DATABASE
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 1 Diabetes
Lead sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Sponsor class: OTHER
First posted: 2012-07-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim this study is the acquisition and management of a data base for the development of the glycaemic regulation algorithms. This database will integrate the measures of blood glucose and the glycaemia level of the Dexcom sensor on a regular time, the injections of insulin delivered by Debiotech JewelPUMP and the level of insulin in the blood. This database will also contain the bolus of insulin injected at meals and the content of meals, the reduction insulin level during physical activity and the quantification of this physical activity. A study will also be conducted to compare the pharmacokinetics of a bolus of insulin identical with the JewelPUMP either the usual pump of the patient.


Eligibility criteria: Inclusion Criteria:

* Patients with diabetes type 1 Treaty by external insulin pump
* Duration of diabetes than 2 years or c indosable peptide
* Practicing insulin functional (IF) or food plan sets
* Patient having a HbA1c \< 10%
* Patient age over 18 years
* Patient having signed the form of collection of free consent and informed
* Patient affiliated with the social security

Exclusion Criteria:

* Patients with diabetes type 2
* Patient pregnant or likely to be
* All serious pathologies that can interfere with the study (in particular kidney or heart failure)
* Psychiatric pathologies incompatible with the study

Primary outcomes:
measure: Percentage of data collected
timeFrame: Blood glucose and insuline will be collected during the hospital stay of patient (in average 25 hours)
Secondary outcomes:
Other outcomes:
Locations:
city: Besancon
country: France
facility: CHU Jean Minjoz
city: Caen
country: France
facility: CHU de Caen
city: Corbeil Essonnes
country: France
facility: Centre Hospitalier Sud Francilien
city: Grenoble
country: France
facility: University Hospital Grenoble
city: Montpellier
country: France
facility: Chu Montpellier
city: Nancy
country: France
facility: CHU de Nancy
city: Toulouse
country: France
facility: CHU Toulouse
Study officials:
affiliation: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
name: Guillaume CHARPENTIER, MD
role: STUDY_CHAIR
affiliation: Central Hospital, Nancy, France
name: Bruno GUERCI, MD PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02428023: B-Thalasaemia Trait and Its Possible Cardioprotective Role
Official title: B-Thalasaemia Trait and Its Possible Cardioprotective Role
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Beta-Thalassemia Trait
Coronary Artery Disease
Keywords: Thalassemia
trait
coronary
stroke
Lead sponsor: 404 General Military Hospital, Larissa
Sponsor class: OTHER
First posted: 2015-04-28
Enrollment: 2500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 57
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 2500 subjects who serve in military units in Thessaly Greece

Brief summary: Our purpose is to investigate whether thallasaemia trait offers protection against cardiovascular events and whether this can be applied to specific characteristics of these people ( better lipid profile , better blood pressure profile) as scientific literature suggests.

Detailed description: Thallasaemia is a major problem , especially in countries around the Mediterranean sea.On the other hand ,thallasaemia trait has been shown ,in a small number of studies , to have a possible protective role against CAD and stroke.These kind of studies have been contacted in Greece also ,and usually they enroll a small number of participants. In the study, investigators will enroll 2500 subjects who serve in military units in Thesally Greece. Firstly investigators will estimate the prevalence of thallasaemia trait in this population , as it is very high in this region and at the same time investigators will retrospectively record data from their personal files (which are annually recorded).

Eligibility criteria: Inclusion Criteria:

1. voluntary participation,
2. Subjects with Thalassemia treat will be confirmed of their treat by electrophoresis -

Exclusion Criteria:

-

Primary outcomes:
measure: Cardioprotective role of Thalassemia Treat
timeFrame: 1 YEAR
Secondary outcomes:
Other outcomes:
Locations:
city: Larissa
country: Greece
facility: 404 Military Hospital
Study officials:
affiliation: 404 General Military Hospital, Larissa
name: Elias Andreanidis, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00723723: Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
Official title: Compliance With LDL-Lowering Therapy For Secondary Prevention of Coronary Heart Disease in Real Life Practice
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Heart Disease
Hypercholesterolemia
Hyperlipidemia
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2008-07-29
Enrollment: 555
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients being treated with a statin for secondary prevention of coronary heart disease

Brief summary: This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.


Eligibility criteria: Inclusion Criteria:

* willingness to participate in the study
* 18 years of age or more
* clinically established cardiovascular disease to be considered as patients in secondary prevention
* prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol) at last lipid check performed

Exclusion Criteria:

* None

Primary outcomes:
measure: percentage of patients reaching target LDL levels
timeFrame: 6-8 weeks after first visit and 28-32 weeks after first visit
Secondary outcomes:
measure: measure patient compliance to treatment as assessed by counting returned tablets
timeFrame: 6-8 weeks after first visit and 28-32 weeks after first visit
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03310723: Pre-Oxygenation Techniques in Pregnancy
Official title: A Comparison of Pre-oxygenation Techniques in Pregnant Patients Prior to a Cesarean Delivery - A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Preoxygenation
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2017-10-16
Enrollment: 40
Sex: FEMALE
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A trial comparing outcomes of two pre-oxygenation techniques in obstetric patients.

Detailed description: Pre-oxygenation is performed prior to general anesthesia to prevent hypoxia during airway management. It is typically performed using a standard tight-fitting face mask; however, recent advances in oxygenation have occurred through the use of trans-nasal oxygen delivery devices, such as OptiFlow. There is limited evidence of the use of OptiFlow in the pregnant patient, and as such, this study aims to show that OptiFlow is as effective at pre-oxygenation as a standard tight-fitting face-mask technique in the pregnant population.

Eligibility criteria: Inclusion Criteria:

* Healthy (American Society of Anesthesiologists class 1 or 2), pregnant patients ≥36 weeks gestation scheduled for elective Cesarean delivery under neuraxial anesthesia.

Exclusion Criteria:

* Comorbidities likely to alter outcome of respiration and gas exchange.
* Patients only able to breathe through their mouth.
* Patients who are in active labour.
* Patients unable to tolerate a face mask being held over their mouth and nose.
* Patients with a Body Mass Index ≥40kg/m2.
* Patients who are unable to give informed consent.

Primary outcomes:
measure: End Tidal Oxygen Concentration (ETO2) Following Tidal Volume Breathing Using Either Face Mask or OptiFlow
timeFrame: From baseline ETO2 concentration to the end of 3 minutes of tidal volume breathing
Secondary outcomes:
measure: End Tidal Oxygen Concentration (ETO2) Following Vital Capacity Breaths Using Either Face Mask or OptiFlow
timeFrame: From baseline ETO2 concentration to the end of 8 vital capacity breaths (approximately 3 minutes)
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: BC Women's Hospital
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Anton Chau, MD MMSc
role: PRINCIPAL_INVESTIGATOR
References: